| Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update BR Ferrell, JS Temel, S Temin, ER Alesi, TA Balboni, EM Basch, JI Firn, ... Journal of Clinical Oncology 35 (1), 96-112, 2017 | 2093 | 2017 |
| American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care TJ Smith, S Temin, ER Alesi, AP Abernethy, TA Balboni, EM Basch, ... Journal of clinical oncology 30 (8), 880-887, 2012 | 1599 | 2012 |
| Palliative care for patients with cancer: ASCO guideline update JJ Sanders, S Temin, A Ghoshal, ER Alesi, ZV Ali, C Chauhan, JF Cleary, ... Journal of Clinical Oncology 42 (19), 2336-2357, 2024 | 58 | 2024 |
| An overview of chemotoxicity and radiation toxicity in cancer therapy V Yazbeck, E Alesi, J Myers, MH Hackney, L Cuttino, DA Gewirtz Advances in Cancer Research 155, 1-27, 2022 | 47 | 2022 |
| Opportunities for targeting the fatigue-anorexia-cachexia symptom cluster ER Alesi, E Del Fabbro The Cancer Journal 20 (5), 325-329, 2014 | 19 | 2014 |
| Doing palliative care in the oncology office MJ Cheng, LM King, ER Alesi, TJ Smith Journal of oncology practice 9 (2), 84, 2013 | 19 | 2013 |
| Palliative care and oncology partnerships in real practice ER Alesi, D Fletcher, MD Cameron Muir, R Beveridge, TJ Smith Oncology 25 (13), 1287, 2011 | 19 | 2011 |
| Early FDG/PET scanning as a pharmacodynamic marker of anti-EGFR antibody activity in colorectal cancer GW Krystal, E Alesi, JL Tatum Molecular Cancer Therapeutics 11 (7), 1385-1388, 2012 | 18 | 2012 |
| How we do it: Guiding patients facing decisions about “futile” chemotherapy E Alesi, B Bobb, TJ Smith The journal of supportive oncology 9 (5), 184, 2011 | 14 | 2011 |
| Development of the CASH assessment tool to address existential concerns in patients with serious illness ER Alesi, TR Ford, CJ Chen, DS Fletcher, TD Morel, BT Bobb, ... Journal of Palliative Medicine 18 (1), 71-75, 2015 | 12 | 2015 |
| Pembrolizumab plus carboplatin and paclitaxel as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-B10): a single-arm Phase IV trial M Dzienis, J Cundom, CS Fuentes, A Spreafico, M Nordlinger, AV Pastor, ... Journal of Clinical Oncology 42 (25), 2989-2999, 2024 | 6 | 2024 |
| Advances in Cancer Research V Yazbeck, E Alesi, J Myers, MH Hackney, L Cuttino, DA Gewirtz Elsevier, 2022 | 6 | 2022 |
| Integrating palliative care into oncology care: confronting the barriers ER Alesi, DS Fletcher Oncology 27 (1), 36-36, 2013 | 3 | 2013 |
| Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI. C Aggarwal, D Sterman, ER Alesi, F Maldonado, R Mehra, CM Bestvina, ... Journal of Clinical Oncology 42 (16_suppl), 8634-8634, 2024 | 1 | 2024 |
| CTEP 10492, a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma. MD Mattes, H Willers, Y Lin, LA Gharzai, ER Alesi, CE Lominska, S Kim, ... Journal of Clinical Oncology 42 (16_suppl), TPS6127-TPS6127, 2024 | 1 | 2024 |
| MA16. 08 Impact of Site of CAN-2409 Injection Plus Continued Immune Checkpoint Inhibitor (ICI) In CI-resistant stage III/IV NSCLC D Sterman, C Aggarwal, ER Alesi, F Maldonado, R Mehra, C Bestvina, ... Journal of Thoracic Oncology 19 (10), S123, 2024 | | 2024 |
| Trial in Progress: CTEP 10492, A Phase 1/1b Study of the AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Squamous Cell Carcinoma MD Mattes, H Willers, Y Lin, LA Gharzai, E Alesi, CE Lominska, S Kim, ... International Journal of Radiation Oncology, Biology, Physics 120 (2), e771, 2024 | | 2024 |
| Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data. Z Hamedi, AY Lo, JD Berkman, ER Alesi Journal of Clinical Oncology 42 (16_suppl), 6022-6022, 2024 | | 2024 |
| Final Analysis of the Phase 4 KEYNOTE-B10 Study: First-Line (1L) Pembrolizumab (pembro)+ Carboplatin (carbo)+ Paclitaxel (pacli) for Recurrent/Metastatic (R/M) Head and Neck … M Dzienis, J Cundom, CS Fuentes, A Spreafico, MJ Nordlinger, AV Pastor, ... International Journal of Radiation Oncology* Biology* Physics 118 (5), e3-e4, 2024 | | 2024 |
| Palliating oncologists: A pilot study on primary palliative care development in hematology-oncology trainee outpatient clinics. ER Alesi, S Rauenzahn, L Lyckholm Journal of Clinical Oncology 32 (31_suppl), 21-21, 2014 | | 2014 |
